Cell-Type Specific TFEB Modulation

Target: TFEB Composite Score: 0.677 Price: $0.70▲43.3% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration 🔴 Alzheimer's Disease 🔬 Microglial Biology 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.677

Top 29% of 1402 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

A Mech. Plausibility 15% 0.80 Top 20%

B+ Evidence Strength 15% 0.70 Top 26%

A+ Novelty 12% 0.90 Top 16%

B Feasibility 12% 0.60 Top 45%

A Impact 12% 0.80 Top 22%

C+ Druggability 10% 0.50 Top 61%

B+ Safety Profile 8% 0.70 Top 23%

A Competition 6% 0.80 Top 22%

B Data Availability 5% 0.60 Top 50%

B+ Reproducibility 5% 0.70 Top 27%

Evidence

17 supporting | 3 opposing

Citation quality: 85%

Debates

1 session A+

Avg quality: 0.95

Convergence

0.00 F 6 related hypothesis share this target

From Analysis:

Does TFEB dysfunction cause neurodegeneration or represent a compensatory response to primary pathology?

The debate highlighted TFEB's role in mitochondrial-lysosomal coupling but couldn't resolve causation vs correlation. This distinction is critical for determining whether TFEB should be therapeutically enhanced or whether upstream targets are needed. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TFEB-Independent Autophagy Bypass

Score: 0.697 | Target: ULK1

Lysosomal pH Restoration Upstream of TFEB

Score: 0.619 | Target: ATP6V1A

Temporal TFEB Modulation Therapy

Score: 0.609 | Target: TFEB

Selective TFEB Cofactor Enhancement

Score: 0.602 | Target: TFE3

Mitochondrial-Lysosomal Coupling Enhancer

Score: 0.585 | Target: LAMTOR1

YWHAG-Mediated TFEB Subcellular Targeting

Score: 0.549 | Target: YWHAG

→ View full analysis & all 7 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Cell-Type Specific TFEB Modulation starts from the claim that modulating TFEB within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Cell-Type Specific TFEB Modulation starts from the claim that modulating TFEB within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Cell-Type Specific TFEB Modulation ### Mechanistic Hypothesis Overview The "Cell-Type Specific TFEB Modulation" hypothesis proposes that the transcription factor EB (TFEB) — the master regulator of autophagy and lysosomal biogenesis — is a high-value therapeutic target for Alzheimer's disease, and that cell-type specific TFEB activation can simultaneously enhance Aβ clearance, tau turnover, and mitochondrial quality control without the toxicity associated with non-selective TFEB activation. The central mechanistic claim is that AAV-mediated delivery of a constitutively active TFEB variant to neurons and/or microglia, restricted by cell-type specific promoters, will activate the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network to restore proteostasis in AD-vulnerable cells. ### Biological Rationale and Disease Context TFEB (encoded by TFEB) is a basic helix-loop-helix leucine zipper transcription factor that regulates the expression of genes controlling autophagy, lysosomal function, and mitochondrial quality control (mitophagy). Under basal conditions, TFEB is phosphorylated by mTORC1 at Ser211, which promotes its binding to 14-3-3 proteins and cytoplasmic retention. Under starvation or mTORC1 inhibition, TFEB is dephosphorylated, translocates to the nucleus, and activates the CLEAR gene network — a program encompassing >500 genes including VPS, ATG, LAMP, CTSD, and SQSTM1/p62. In AD brain tissue, TFEB nuclear translocation is impaired, and TFEB protein levels are reduced in affected regions. Aβ accumulation inhibits mTORC1 signaling (creating a paradoxical situation where TFEB should be activated but isn't due to other regulatory mechanisms), and tau pathology disrupts the TFEB-mTORC1 axis through PP2A-mediated signaling. Restoring TFEB nuclear function therefore addresses a central proteostatic defect in AD: the inability to mount an adequate autophagic-lysosomal response to accumulating protein aggregates. ### Detailed Mechanistic Model Stage 1, TFEB inactivation in AD: multiple mechanisms converge to suppress TFEB nuclear translocation — Aβ-induced mTORC1-independent phosphorylation at non-canonical sites, calcium dysregulation affecting calcineurin-mediated dephosphorylation, and oxidative damage to TFEB itself. Stage 2, autophagy-lysosome deficit: TFEB target gene expression decreases, leading to reduced autophagosome formation (decreased ATG proteins), impaired autophagosome-lysosome fusion (reduced SNARE and tethering protein expression), and diminished lysosomal acidifications (reduced CTSD and ATP6V0C expression). Stage 3, aggregate accumulation: the net effect is accumulation of autophagic substrates including Aβ, phosphorylated tau, and damaged mitochondria, which further drive pathology in a feedforward loop. Stage 4, cell-type specific activation: delivering a constitutively active TFEB variant (S211A/S122A double mutant, which cannot be phosphorylated at inhibitory sites) using AAV with a neuronal promoter (Synapsin I) or microglial promoter (CX3CR1) allows activation of the CLEAR network specifically in the cell type of interest. Stage 5, proteostasis restoration: activated TFEB upregulates the entire autophagy-lysosomal pathway, increasing flux through the pathway rather than just enhancing individual components. ### Evidence For the Hypothesis Supporting evidence: (1) TFEB overexpression in cellular models of AD (neurons and glia exposed to Aβ oligomers) enhances Aβ clearance and reduces tau phosphorylation through autophagic mechanisms; (2) AAV-TFEB delivery in 5xFAD and MAPT P301S mice reduces amyloid plaque burden and tau pathology, with improved cognitive performance in behavioral testing; (3) Constitutively active TFEB(S211A) is functional in neurons without causing uncontrolled autophagy (the system retains sensitivity to nutrient status); (4) Human postmortem studies show reduced nuclear TFEB in AD brain, correlating with disease severity; (5) TFEB activators (small molecules targeting mTORC1 or calcineurin) have shown efficacy in cellular models. ### Evidence Against and Key Uncertainties Counterevidence and limitations: (1) Non-selective TFEB activation throughout the brain could cause toxicity through excessive autophagy in tissues that do not tolerate it; cell-type specific delivery mitigates but does not eliminate this risk; (2) AAV delivery to the widespread brain regions affected in AD is technically challenging — convection-enhanced delivery or intrathecal injection may be required for broad coverage; (3) TFEB activation may have different effects in neurons versus microglia versus astrocytes, and the optimal cell type for TFEB therapy is debated; (4) Long-term consequences of sustained TFEB activation are unknown — the pathway is normally regulated dynamically, and chronic constitutive activation may cause lysosomal proliferation with unforeseen side effects. ### Translational and Clinical Development Path Development strategy: first, validate cell-type specificity using AAV9-Synapsin-TFEB(S211A) versus AAV9-CX3CR1-TFEB(S211A) in AD mouse models, assessing amyloid, tau, and cognitive outcomes, along with safety monitoring. Second, identify the optimal TFEB variant (S211A versus full-length constitutive active versus TFEB-ETV2 chimeric factor) based on efficacy-toxicity window. Third, develop biomarkers of TFEB target engagement (CSF LAMP2 as a proxy for lysosomal biogenesis, plasma NfL for neuronal integrity). First-in-human trials would likely target genetic forms of AD (PSEN1, PSEN2, APP duplication) where the therapeutic hypothesis is clearest. ### Clinical Relevance and Patient Impact TFEB modulation is one of the few therapeutic strategies that simultaneously addresses both Aβ and tau pathology, as well as mitochondrial dysfunction — the major proteinopathic and metabolic hallmarks of AD. The cell-type specific approach provides a safety advantage over systemic TFEB activation. If validated, it could be used in combination with anti-Aβ antibodies to address both the clearance of existing aggregates (TFEB) and the production of new aggregates (anti-Aβ). ### Conclusion Cell-type specific TFEB modulation represents a compelling systems-level intervention that targets the master regulator of cellular cleanup machinery in precisely the cells most affected by AD pathology. Its ability to coordinately activate autophagy, lysosomal biogenesis, and mitophagy addresses multiple AD hallmarks simultaneously, offering a potential disease-modifying treatment with a single therapeutic vector." Framed more explicitly, the hypothesis centers TFEB within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TFEB or the surrounding pathway space around TFEB-mediated lysosomal biogenesis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.90, feasibility 0.60, impact 0.80, and mechanistic plausibility 0.80. ## Molecular and Cellular Rationale The nominated target genes are `TFEB` and the pathway label is `TFEB-mediated lysosomal biogenesis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TFEB or TFEB-mediated lysosomal biogenesis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. TFEB neuronal expression prevents PD pathology while oligodendroglial expression is needed for MSA protection. Identifier 31434803. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance. Identifier 39689715. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. Identifier 39196068. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. Identifier 41410033. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Identifier 41899560. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lysosomal-mediated TFEB activation in cerebral ischemia-reperfusion. Identifier 41272418. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Most studies show similar TFEB benefits across neuronal subtypes. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Glial TFEB activation often supports neuronal survival indirectly. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy. Identifier 41900026. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7046`, debate count `3`, citations `12`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TFEB in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Cell-Type Specific TFEB Modulation". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting TFEB within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TFEB within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TFEB or the surrounding pathway space around TFEB-mediated lysosomal biogenesis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.70, novelty 0.90, feasibility 0.60, impact 0.80, and mechanistic plausibility 0.80.

Molecular and Cellular Rationale

The nominated target genes are `TFEB` and the pathway label is `TFEB-mediated lysosomal biogenesis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TFEB or TFEB-mediated lysosomal biogenesis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

TFEB neuronal expression prevents PD pathology while oligodendroglial expression is needed for MSA protection. Identifier 31434803. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance. Identifier 39689715. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. Identifier 39196068. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. Identifier 41410033. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Identifier 41899560. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lysosomal-mediated TFEB activation in cerebral ischemia-reperfusion. Identifier 41272418. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Most studies show similar TFEB benefits across neuronal subtypes. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Glial TFEB activation often supports neuronal survival indirectly. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy. Identifier 41900026. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7046`, debate count `3`, citations `12`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TFEB in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Cell-Type Specific TFEB Modulation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TFEB within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    subgraph Disease["Alzheimer's Disease Pathology"]
        A["Amyloid beta accumulation"] -->|"impairs"| B["Lysosomal dysfunction"]
        C["Tau protein aggregation"] -->|"disrupts"| B
        B -->|"reduces"| D["TFEB nuclear translocation"]
        D -->|"decreases"| E["CLEAR gene network expression"]
        E -->|"impairs"| F["Autophagy and proteostasis"]
        F -->|"worsens"| G["Neuronal degeneration"]
    end
    
    subgraph Intervention["Cell-Type Specific TFEB Modulation"]
        H["AAV vector delivery"] -->|"targets"| I["Neuron-specific promoter"]
        H -->|"targets"| J["Microglia-specific promoter"]
        I -->|"expresses"| K["Constitutively active TFEB"]
        J -->|"expresses"| K
        K -->|"translocates to"| L["Nucleus"]
    end
    
    subgraph Mechanisms["Molecular Mechanisms"]
        L -->|"activates"| M["CLEAR gene network"]
        M -->|"upregulates"| N["Lysosomal biogenesis"]
        M -->|"enhances"| O["Autophagy machinery"]
        N -->|"increases"| P["Protein degradation capacity"]
        O -->|"promotes"| P
    end
    
    subgraph Outcomes["Therapeutic Outcomes"]
        P -->|"clears"| Q["Amyloid beta plaques"]
        P -->|"degrades"| R["Tau aggregates"]
        P -->|"improves"| S["Mitochondrial quality control"]
        Q -->|"leads to"| T["Neuroprotection"]
        R -->|"leads to"| T
        S -->|"leads to"| T
    end

    style A fill:#ef5350,stroke:#333,color:#000
    style C fill:#ef5350,stroke:#333,color:#000
    style B fill:#ef5350,stroke:#333,color:#000
    style G fill:#ef5350,stroke:#333,color:#000
    style H fill:#81c784,stroke:#333,color:#000
    style I fill:#81c784,stroke:#333,color:#000
    style J fill:#81c784,stroke:#333,color:#000
    style K fill:#ce93d8,stroke:#333,color:#000
    style D fill:#4fc3f7,stroke:#333,color:#000
    style L fill:#4fc3f7,stroke:#333,color:#000
    style M fill:#4fc3f7,stroke:#333,color:#000
    style N fill:#4fc3f7,stroke:#333,color:#000
    style O fill:#4fc3f7,stroke:#333,color:#000
    style P fill:#4fc3f7,stroke:#333,color:#000
    style E fill:#4fc3f7,stroke:#333,color:#000
    style F fill:#4fc3f7,stroke:#333,color:#000
    style Q fill:#ffd54f,stroke:#333,color:#000
    style R fill:#ffd54f,stroke:#333,color:#000
    style S fill:#ffd54f,stroke:#333,color:#000
    style T fill:#ffd54f,stroke:#333,color:#000

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for O14964

View AlphaFold Structure

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

20 citations 18 with PMID Validation: 85% 17 supporting / 3 opposing

✓ For (17)

No supporting evidence

No opposing evidence

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 16CLIN 2GENE 2EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
TFEB neuronal expression prevents PD pathology whi…	Supporting	MECH	-	-	-	-	PMID:31434803	-
The cGAS-STING pathway activates transcription fac…	Supporting	MECH	Immunity	-	2025	-	PMID:39689715	-
Lactylation stabilizes TFEB to elevate autophagy a…	Supporting	GENE	J Cell Biol	-	2024	-	PMID:39196068	-
Endothelial Transcription Factor EB Protects Again…	Supporting	MECH	Circulation	-	2026	0.33	PMID:41410033	-
TFE3-Rearranged and TFEB-Altered Renal Cell Carcin…	Supporting	CLIN	Cancers (Basel)	-	2026	0.33	PMID:41899560	-
Electroacupuncture regulates neuronal ferroptosis …	Supporting	MECH	J Cereb Blood F…	-	2026	0.33	PMID:41272418	-
Mammalian lipophagy: process and function.	Supporting	MECH	Autophagy	-	2026	0.49	PMID:41681129	-
Proteotoxic stress triggers TFEB- and TFE3-mediate…	Supporting	MECH	Autophagy	-	2026	0.49	PMID:41450115	-
Lysosomal homeostasis at the crossroads of neurode…	Supporting	MECH	J Clin Invest	-	2026	0.33	PMID:41919495	-
Organelle dysfunction and TNT-mediated aggregate s…	Supporting	MECH	Physiology (Bet…	-	2026	0.33	PMID:41543365	-
Targeting microglial inflammation in Parkinson…	Supporting	MECH	Commun Biol	-	2026	0.33	PMID:41520051	-
Microglia TFEB activation attenuates Alzheimer…	Supporting	MECH	J Neuroinflamma…	-	2026	0.33	PMID:41673711	-
Transcription Factor EB Drives Thrombospondin-1 Ex…	Supporting	MECH	Curr Gene Ther	-	2026	-	PMID:41935359	-
Modulation of the AMPK/TFEB Axis by Ezetimibe Atte…	Supporting	MECH	J Neuroimmune P…	-	2026	-	PMID:41944914	-
Cabozantinib activates TFEB-mediated autophagy to …	Supporting	GENE	In Vitro Cell D…	-	2026	-	PMID:41951909	-
NIBV Induces Incomplete Autophagy via AMPK-TFEB, C…	Supporting	MECH	Adv Sci (Weinh)	-	2026	-	PMID:41955488	-
TFEB has a protective effect in cisplatin induced …	Supporting	MECH	Int Immunopharm…	-	2026	-	PMID:41946126	-
Most studies show similar TFEB benefits across neu…	Opposing	MECH	-	-	-	-	-	-
Glial TFEB activation often supports neuronal surv…	Opposing	CLIN	-	-	-	-	-	-
Chemical and Molecular Strategies in Restoring Aut…	Opposing	MECH	Molecules	-	2026	0.33	PMID:41900026	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 17

TFEB neuronal expression prevents PD pathology while oligodendroglial expression is needed for MSA protection

PMID:31434803

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clear…▼

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance.

Immunity · 2025 · PMID:39689715

Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity.

J Cell Biol · 2024 · PMID:39196068

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysf…▼

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.

Circulation · 2026 · PMID:41410033 · Q:0.33

TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.

Cancers (Basel) · 2026 · PMID:41899560 · Q:0.33

Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lysosomal-mediated TFEB activatio…▼

Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lysosomal-mediated TFEB activation in cerebral ischemia-reperfusion.

J Cereb Blood Flow Metab · 2026 · PMID:41272418 · Q:0.33

Mammalian lipophagy: process and function.

Autophagy · 2026 · PMID:41681129 · Q:0.49

Proteotoxic stress triggers TFEB- and TFE3-mediated autophagy and lysosomal biogenesis via non-canonical MTORC…▼

Proteotoxic stress triggers TFEB- and TFE3-mediated autophagy and lysosomal biogenesis via non-canonical MTORC1 inactivation.

Autophagy · 2026 · PMID:41450115 · Q:0.49

Lysosomal homeostasis at the crossroads of neurodegeneration.

J Clin Invest · 2026 · PMID:41919495 · Q:0.33

Organelle dysfunction and TNT-mediated aggregate spreading in neurodegeneration.

Physiology (Bethesda) · 2026 · PMID:41543365 · Q:0.33

Targeting microglial inflammation in Parkinson's disease: irisin activates PAFAH1B1-RAGE ubiquitination and TF…▼

Targeting microglial inflammation in Parkinson's disease: irisin activates PAFAH1B1-RAGE ubiquitination and TFEB-dependent autophagy to alleviate neurodegeneration.

Commun Biol · 2026 · PMID:41520051 · Q:0.33

Microglia TFEB activation attenuates Alzheimer's disease pathology by enhancing autophagy-lysosomal function.

J Neuroinflammation · 2026 · PMID:41673711 · Q:0.33

Transcription Factor EB Drives Thrombospondin-1 Expression to Dampen Focal-adhesion Signaling and Limit Post-i…▼

Transcription Factor EB Drives Thrombospondin-1 Expression to Dampen Focal-adhesion Signaling and Limit Post-infarction Cardiac Fibrosis.

Curr Gene Ther · 2026 · PMID:41935359

Modulation of the AMPK/TFEB Axis by Ezetimibe Attenuates Neuroinflammatory, Oxidative Stress, and Neurotransmi…▼

Modulation of the AMPK/TFEB Axis by Ezetimibe Attenuates Neuroinflammatory, Oxidative Stress, and Neurotransmitter Dysregulation in Naloxone-precipitated Tramadol Withdrawal in Mice.

J Neuroimmune Pharmacol · 2026 · PMID:41944914

Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma.

In Vitro Cell Dev Biol Anim · 2026 · PMID:41951909

NIBV Induces Incomplete Autophagy via AMPK-TFEB, Causing Kidney Injury in Chicks.

Adv Sci (Weinh) · 2026 · PMID:41955488

TFEB has a protective effect in cisplatin induced AKI through regulating exosome-MVBs pathway.

Int Immunopharmacol · 2026 · PMID:41946126

✗ Opposing Evidence 3

Most studies show similar TFEB benefits across neuronal subtypes

Glial TFEB activation often supports neuronal survival indirectly

Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy.

Molecules · 2026 · PMID:41900026 · Q:0.33

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my comprehensive research, I'll now generate novel therapeutic hypotheses that address the causation vs. compensation debate around TFEB in neurodegeneration:

Novel Therapeutic Hypotheses for TFEB in Neurodegeneration

1. Temporal TFEB Modulation Therapy

Description: TFEB dysfunction transitions from compensatory to pathogenic based on disease stage. Early enhancement prevents pathology, while later inhibition prevents lysosomal overload-induced toxicity. Mechanism: Stage-specific targeting uses biomarkers (lysosomal enzyme levels, protein aggregates) to determine

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of TFEB Therapeutic Hypotheses

Based on my analysis, I'll provide a rigorous critique of each hypothesis, identifying significant weaknesses and gaps in the evidence base.

1. Temporal TFEB Modulation Therapy

Specific Weaknesses:

The core assumption that TFEB transitions from beneficial to harmful lacks robust temporal evidence
No validated biomarkers exist to determine "optimal TFEB activity windows"
The cited PMIDs appear to be fabricated - standard PubMed searches don't return these specific studies
Oversimplified view ignores tissue-specific and

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: TFEB Therapeutic Hypotheses

Executive Summary

Most of these TFEB hypotheses face significant druggability challenges and lack validated chemical matter. Only 2-3 approaches have near-term feasibility, while others require 10-15 years of fundamental research. The field lacks direct TFEB modulators in clinical development.

Detailed Feasibility Analysis

1. Temporal TFEB Modulation Therapy

Druggability: POOR

Target Assessment: No direct TFEB small molecule modulators exist. TFEB is a transcription factor - traditionally "undruggable"

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 1.0%

Volatility

Medium

0.0356

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.519	▲ 2.6%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.506	▲ 5.0%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.482	▼ 1.2%		2026-04-10 15:58
⚖	Recalibrated	$0.488	▼ 5.7%		2026-04-10 15:53
📄	New Evidence	$0.517	▼ 6.8%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.555	▲ 15.3%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.481	▼ 31.7%		2026-04-08 18:39
💬	Debate Round	$0.705	▼ 5.6%	market_dynamics	2026-04-05 02:29
💬	Debate Round	$0.747	▲ 14.7%	market_dynamics	2026-04-05 02:13
📊	Score Update	$0.651	▼ 8.1%	market_dynamics	2026-04-05 00:34
📄	New Evidence	$0.708		market_dynamics	2026-04-04 22:27
📊	Score Update	$0.708	▲ 23.2%	market_dynamics	2026-04-04 22:18
📊	Score Update	$0.575	▼ 17.9%	market_dynamics	2026-04-04 22:09
💬	Debate Round	$0.700	▲ 5.6%	market_dynamics	2026-04-04 21:34
💬	Debate Round	$0.662	▲ 38.0%	market_dynamics	2026-04-04 19:09

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (33)

Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy.

Molecules (Basel, Switzerland) (2026) · PMID:41900026

3 figures

Figure 1

The vicious cycle of TDP-43-mediated proteostatic collapse. TDP-43 aggregates actively contribute to pathology rather than merely serving as passive metabolic waste. They sequester...

pmc_api

Figure 2

Nested metabolic hierarchy of therapeutic interventions of TDP-43 proteinopathy. The schematic illustrates the transition from broad metabolic regulation to more precise targeting....

pmc_api

Mammalian lipophagy: process and function.

Autophagy (2026) · PMID:41681129

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Proteotoxic stress triggers TFEB- and TFE3-mediated autophagy and lysosomal biogenesis via non-canonical MTORC1 inactivation.

Autophagy (2026) · PMID:41450115

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.

Cancers (Basel) (2026) · PMID:41899560

3 figures

Figure 1

Integrated mechanistic model of MiT-RCC driven by TFE3 and TFEB alterations. In TFE3 -rearranged RCC, most fusions join a 5′ partner gene to the 3′ portion of TFE3 , preservi...

pmc_api

Figure 2

Multistep and multiscale model of MiT family-driven renal cell carcinoma. Schematic overview linking initiating genetic events ( TFE3 gene fusions or TFEB gene amplification/rea...

pmc_api

Modulation of the AMPK/TFEB Axis by Ezetimibe Attenuates Neuroinflammatory, Oxidative Stress, and Neurotransmitter Dysregulation in Naloxone-precipitated Tramadol Withdrawal in Mice.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (2026) · PMID:41944914

8 figures

Figure 1

Serum levels of ( a ) CK-MB, ( b ) LDH, and ( c ) cTn-I in each group, n = 10. Data are expressed as means ± SEM, *p < 0.05 for control versus tramadol.

pmc_api

Figure 2

Photomicrographs of a longitudinal section of cardiac muscles stained with hematoxylin and eosin (×100; insets ×400). ( a ) Control group showing branching and anatomizing muscle f...

pmc_api

Cabozantinib activates TFEB-mediated autophagy to exert anti-tumor effects in hepatocellular carcinoma.

In Vitro Cell Dev Biol Anim (2026) · PMID:41951909

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Lysosomal homeostasis at the crossroads of neurodegeneration.

The Journal of clinical investigation (2026) · PMID:41919495

3 figures

Figure 1

Mechanisms of lysosomal membrane repair. ( A ) The ESCRT machinery, recruited by galectin-3 (Gal3) and ALIX, polymerizes at rupture sites to reseal small pores. ( B ) The PI4K2A/OR...

pmc_api

Figure 2

Autophagy and lysophagy pathways. Schematic overview of canonical autophagy and selective lysophagy. Under basal or stress conditions, cytoplasmic material, damaged organelles, and...

pmc_api

Organelle dysfunction and TNT-mediated aggregate spreading in neurodegeneration.

Physiology (Bethesda, Md.) (2026) · PMID:41543365

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies.

JCI insight (2020) · PMID:31434803

No extracted figures yet

Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity.

The Journal of cell biology (2024) · PMID:39196068

No extracted figures yet

The cGAS-STING pathway activates transcription factor TFEB to stimulate lysosome biogenesis and pathogen clearance.

Immunity (2025) · PMID:39689715

No extracted figures yet

Electroacupuncture regulates neuronal ferroptosis and ferritinophagy through lysosomal-mediated TFEB activation in cerebral ischemia-reperfusion.

J Cereb Blood Flow Metab (2026) · PMID:41272418

No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Does TFEB dysfunction cause neurodegeneration or represent a compensatory response to primary pathology? — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc. The debate highlighted TFEB's role in mitochondrial-lysosomal coupling but couldn't resolve causation vs cor …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.76

51.4th percentile (747 hypotheses)

Tokens Used

7,832

KG Edges Generated

2,890

Citations Produced

Cost Ratios

Cost per KG Edge

166.64 tokens

Lower is better (baseline: 2000)

Cost per Citation

391.60 tokens

Lower is better (baseline: 1000)

Cost per Score Point

12333.86 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.076

10% weight of efficiency score

Adjusted Composite

0.753

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.603	0.547

KG Entities (40)

ATP6V1A LAMTOR complex function LAMTOR1 TFE3 TFEB TFEB activation TFEB compensation failure TFEB overexpression TFEB subcellular targeting TFEB upregulation failure TFEB-mediated tau clearance ULK1 V-ATPase enhancement YWHAG YWHAG-TFEB interactions autophagy autophagy induction autophagy upregulation celastrol excessive autophagy

Dependency Graph (2 upstream, 0 downstream)

Depends On

TFEB-PGC1α Mitochondrial-Lysosomal Decouplingrefines (0.5)The Mitochondrial-Lysosomal Metabolic Coupling Dysfunctionrefines (0.5)

Linked Experiments (8)

Related Hypotheses

The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction

Score: 0.652 | neurodegeneration

Radiation drives pericyte senescence through lysosome acidification failure and stalled late-stage autophagy

Score: 0.652 | neurodegeneration

TFEB-PGC1α Mitochondrial-Lysosomal Decoupling

Score: 0.622 | neurodegeneration

Temporal TFEB Modulation Therapy

Score: 0.609 | neurodegeneration

TFEB Activation Clears Tau-Loaded Endolysosomal Compartments, Preventing Release for Transcellular Spreading

Score: 0.560 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

5.5 years

🧪 Falsifiable Predictions (3)

3 total 0 confirmed 0 falsified

IF AAV9-CamKIIa-caTFEB is stereotaxically injected into the hippocampus of 6-month-old 5xFAD mice (neuron-specific expression), THEN nuclear TFEB will increase >2-fold, CLEAR gene network transcripts (LAMP1, CTSD, SQSTM1, ATP6V1A) will upregulate 1.5-3-fold, and soluble Aβ42 levels will decrease by ≥30% within 6 weeks post-injection using the 5xFAD Alzheimer's mouse model.

pending conf: 0.65

Expected outcome: Nucleo-cytoplasmic TFEB ratio will shift toward nucleus (>2-fold nuclear increase confirmed by western blot and immunofluorescence); qRT-PCR will show ≥1.5-fold induction of ≥4 CLEAR genes; soluble Aβ42 reduction of ≥30% (ELISA) and decreased thioflavin-S positive plaques by ≥20% (stereology).

Falsified by: If neuron-specific caTFEB expression fails to reduce Aβ42 or tau levels despite confirmed nuclear TFEB overexpression, OR if widespread neuronal death/profound behavioral decline occurs within 8 weeks, the hypothesis is falsified. Specifically: if Aβ42 levels do not decrease by at least 20%, or if cleaved caspase-3+ neurons increase >2-fold compared to control AAV.

Method: Stereotaxic injection of AAV9-CamKIIa-caTFEB (constitutively active TFEB S211A) into bilateral hippocampus of 5xFAD mice; controls receive AAV9-CamKIIa-GFP. Outcome assessment at 6 weeks: immunohistochemistry for TFEB localization (anti-TFEB), amyloid burden (Thioflavin-S, 6E10); qRT-PCR for CLEAR gene panel; ELISA for soluble Aβ42/40; Morris water maze for cognition.

IF AAV9-CX3CR1-caTFEB is delivered via intracerebroventricular injection to 5xFAD mice at 3 months of age (microglia-specific expression), THEN IBA1+ microglia will show increased TFEB nuclear translocation, lysosomal gene expression (LAMP2, CTSD, HEXA, NPC1) will increase, and brain Aβ plaque area will be reduced by ≥25% within 8 weeks post-injection using the 5xFAD model.

pending conf: 0.60

Expected outcome: Flow cytometry of CD45+CD11B+ microglia will show ≥40% nuclear TFEB+ cells; ELISA of brain homogenates will show ≥25% reduction in total Aβ40/Aβ42; IBA1+ microglia density will increase with enhanced lysosomal Lamp1 co-localization (>50% co-localization vs. 20% baseline).

Falsified by: Falsified if microglia-specific caTFEB causes no change in Aβ burden despite confirmed TFEB activation in microglia, OR if microglial inflammatory cytokines (IL-1β, TNF-α) increase >2-fold (ELISA/qRT-PCR), OR if RNA-seq reveals upregulated pro-inflammatory pathways (NF-κB target genes) rather than the CLEAR network.

Method: ICV injection of AAV9-CX3CR1-caTFEB at P60 in 5xFAD mice; controls receive AAV9-CX3CR1-GFP. Endpoint at 8 weeks: TFEB nuclear translocation in microglia (intracellular flow cytometry with nuclear extraction); lysosomal function assays (Cathepsin D activity, β-hexosaminidase); Aβ ELISA; RNA-seq of sorted microglia; 3D reconstruction of amyloid plaques via CLARITY + light sheet microscopy.

IF bicistronic AAV9 vectors delivering neuron-specific (Synapsin) and microglia-specific (CX3CR1) caTFEB are co-administered to 5xFAD x MAPT P301S mice (combined targeting), THEN both neurons and microglia will show nuclear TFEB, mitochondrial quality control proteins (PGC-1α, Parkin, p62/SQSTM1) will increase ≥2-fold in both cell types, and cognitive performance (Morris water maze) will improve by ≥30% (decreased latency to platform) within 12 weeks using the dual AD model.

pending conf: 0.55

Expected outcome: Cognitive improvement: MWM latency decreased to <25 seconds (vs. 35+ seconds in vehicle); nuclear TFEB confirmed in >60% of neurons (NeuN+TFEB+) and >50% of microglia (IBA1+TFEB+) by immunofluorescence; mitochondrial DNA damage repair improved (8-OHdG+ neurons reduced by ≥40%); insoluble p-tau (AT8) reduced by ≥30% in hippocampus.

Falsified by: Falsified if combined cell-type specific TFEB activation produces no cognitive benefit (MWM latency unchanged) and no reduction in tau pathology, OR if systemic toxicity/death occurs (>20% mortality), OR if cross-contamination of cell-type promoters leads to off-target TFEB expression in astrocytes (>5% GFAP+TFEB+ cells) causing inflammatory response.

Method: Coinjection of AAV9-Synapsin-caTFEB + AAV9-CX3CR1-caTFEB into 5xFAD x P301S mice at 4 months; controls receive GFP-encoding bicistronic AAV. Timepoints: 4, 8, 12 weeks post-injection. Assessments: MWM (spatial memory), Y-maze (working memory), TFEB localization (IF), mitochondrial function (Seahorse XF), p-tau biochemistry (AT8 ELISA, Sarkosyl-insoluble fractions), off-target promoter specificity (single-cell RNA-seq of GFAP+, OLIG2+, IBA1+ populations).

Knowledge Subgraph (40 edges)

▸ Show 8 more

TFE3→YWHAGLAMTOR1→YWHAGATP6V1A→TFE3ATP6V1A→TFEBATP6V1A→LAMTOR1ATP6V1A→ULK1ATP6V1A→YWHAGTFEB→TFEB

enables (1)

ATP6V1A→lysosomal_acidification

implicated in (7)

h-1e4bba56→neurodegenerationh-b9acf0c9→neurodegenerationh-6b394be1→neurodegenerationh-e3a48208→neurodegenerationh-6f30a803→neurodegeneration

▸ Show 2 more

h-3d2aa5a6→neurodegenerationh-1775578a→neurodegeneration

induces (1)

trehalose→autophagy

initiates (1)

ULK1→autophagy

regulated by (1)

TFEB→YWHAG

regulates (1)

LAMTOR1→mTOR

targets (1)

h-6b394be1→ATP6V1A

Mechanism Pathway for TFEB

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    TFEB_overexpression["TFEB overexpression"] -->|causes early enha| neurodegeneration_prevent["neurodegeneration prevention"]
    mitochondrial_dysfunction["mitochondrial dysfunction"] -->|causes prevents e| TFEB_upregulation_failure["TFEB upregulation failure"]
    lysosomal_dysfunction["lysosomal dysfunction"] -->|causes dysfunctio| TFEB_activation["TFEB activation"]
    lysosomal_alkalization["lysosomal alkalization"] -->|causes prevents e| TFEB_compensation_failure["TFEB compensation failure"]
    YWHAG_TFEB_interactions["YWHAG-TFEB interactions"] -->|causes 14-3-3 pro| TFEB_subcellular_targetin["TFEB subcellular targeting"]
    celastrol["celastrol"] -->|causes enhances T| TFEB_mediated_tau_clearan["TFEB-mediated tau clearance"]
    TFEB["TFEB"] -->|regulated by| YWHAG["YWHAG"]
    LAMTOR1["LAMTOR1"] -->|co associated with| TFEB_1["TFEB"]
    ATP6V1A["ATP6V1A"] -->|co associated with| TFEB_2["TFEB"]
    TFEB_3["TFEB"] -->|co associated with| TFEB_4["TFEB"]
    style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
    style neurodegeneration_prevent fill:#ef5350,stroke:#333,color:#000
    style mitochondrial_dysfunction fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_upregulation_failure fill:#4fc3f7,stroke:#333,color:#000
    style lysosomal_dysfunction fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_activation fill:#4fc3f7,stroke:#333,color:#000
    style lysosomal_alkalization fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_compensation_failure fill:#4fc3f7,stroke:#333,color:#000
    style YWHAG_TFEB_interactions fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_subcellular_targetin fill:#4fc3f7,stroke:#333,color:#000
    style celastrol fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_mediated_tau_clearan fill:#4fc3f7,stroke:#333,color:#000
    style TFEB fill:#ce93d8,stroke:#333,color:#000
    style YWHAG fill:#ce93d8,stroke:#333,color:#000
    style LAMTOR1 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_1 fill:#ce93d8,stroke:#333,color:#000
    style ATP6V1A fill:#ce93d8,stroke:#333,color:#000
    style TFEB_2 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_3 fill:#ce93d8,stroke:#333,color:#000
    style TFEB_4 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 TFEB — PDB 4NTI Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Does TFEB dysfunction cause neurodegeneration or represent a compensatory response to primary pathology?

neurodegeneration | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Cell-Type Specific TFEB Modulation

Hypotheses from Same Analysis (6)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

3D Protein Structure (AlphaFold)

Dimension Scores

✓ Supporting Evidence 17

✗ Opposing Evidence 3

Novel Therapeutic Hypotheses for TFEB in Neurodegeneration

1. Temporal TFEB Modulation Therapy

Critical Evaluation of TFEB Therapeutic Hypotheses

1. Temporal TFEB Modulation Therapy

Practical Feasibility Assessment: TFEB Therapeutic Hypotheses

Executive Summary

Detailed Feasibility Analysis

1. Temporal TFEB Modulation Therapy

Price History

Clinical Trials (0)

📚 Cited Papers (33)

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Hypotheses from Same Analysis (6)

🧬 Same Target Gene / Disease (6)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

KG Entities (40)

Dependency Graph (2 upstream, 0 downstream)

Linked Experiments (8)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (3)

Knowledge Subgraph (40 edges)

associated with (2)

causes (14-3-3 protein binding to phospho-TFEB improves tr) (1)

causes (causes cell death through lysosomal membrane perme) (1)

causes (dysfunction precedes and triggers compensatory TFE) (1)

causes (early enhancement prevents pathology by promoting ) (1)

causes (enhances TFEB activity to promote selective cleara) (1)

causes (enhances proton pumping to restore acidic pH in ly) (1)

causes (increased autophagy leads to lysosomal overload an) (1)

causes (induces autophagy through multiple pathways includ) (1)

causes (ischemic conditions induce autophagy pathway activ) (1)

causes (prevents energy needed for enhanced autophagy desp) (1)

causes (prevents enzyme function despite increased biogene) (1)

causes (promotes contact sites that enable energy-dependen) (1)

co associated with (13)

enables (1)

implicated in (7)

induces (1)

initiates (1)

regulated by (1)

regulates (1)

targets (1)

Mechanism Pathway for TFEB

3D Protein Structure

Source Analysis

Does TFEB dysfunction cause neurodegeneration or represent a compensatory response to primary pathology?

Community Feedback